Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Colonic Neoplasms × regorafenib × Clear all

Phase

Phase 2 10 Phase 1 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 16 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasm Metastasis 3 Gastrointestinal Stromal Tumors 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Adenocarcinoma 2 Spinocerebellar Degenerations 1 HER2-positive Colorectal Cancer 1 HER2 IHC3+ Advanced Colorectal Cancer 1 Colorectal Cancer Liver Metastases 1 Colonic Neoplasms 1 Advanced Colorectal Cancer 1

Interventions

Fluorouracil 72 Leucovorin 71 Oxaliplatin 47 Irinotecan 31 Capecitabine 24 Bevacizumab 23 Folfox protocol 20 Cetuximab 15 Chemotherapy, Adjuvant 13 Celecoxib 7 Aspirin 6 Laparoscopy 5 XELOX 4 Panitumumab 4 Neoadjuvant Therapy 4 Levamisole 4 dehydroftorafur 3 Tegafur 3 Surgical Procedures, Operative 3 Observation 3 Floxuridine 3 vatalanib 2 tislelizumab 2 pertuzumab 2 encorafenib 2 atezolizumab 2 Trastuzumab 2 Standard of Care 2 Semaxinib 2 Selenium 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02664077 2022-04-14

ARGO

NSABP Foundation Inc

Phase 3 Terminated

Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡